Düsing Rainer
Dtsch Med Wochenschr. 2020 Jan;145(2):87-91. doi: 10.1055/a-1031-0612. Epub 2020 Jan 20.
Hypertension is defined as resistant to treatment when treatment fails to lower office systolic and diastolic blood pressure values to < 140/90 mmHg. The treatment strategy should include lifestyle measures and appropriate doses of three or more drugs acting by different mechanisms including a diuretic. An updated definition of treatment resistance includes all patients with ≥ 4 antihypertensive agents of different classes irrespective of their on-treatment blood pressure. The term "refractory" hypertension has been suggested for patients with uncontrolled blood pressure on ≥ 5 antihypertensive drugs including the thiazide-like diuretic chlorthalidone and the mineralocorticoid receptor antagonist spironolactone. "Pseudo resistance" especially due to white coat hypertension and non-adherence with the prescribed medication has to be ruled out to be able to identify patients with "true" treatment resistance. Therefore, before distinguishing true from pseudo resistance, the term "apparent" resistance should be used. While the prevalence of apparent resistance may be in the range of 10-15 % of treated patients, the exact prevalence of true resistance remains unknown due to the lack of appropriate studies but is likely to be rather small including a high proportion of patients with secondary forms of hypertension. Once identified most patients with true treatment resistance should receive intensified drug treatment primarily by expanded diuretic usage. Thus, resistant hypertension is primarily a diagnostic challenge: identifying patients with true resistance and those with secondary hypertension.
当治疗无法将诊室收缩压和舒张压降至<140/90 mmHg时,高血压被定义为治疗抵抗。治疗策略应包括生活方式干预措施以及使用三种或更多种作用机制不同的药物,其中包括利尿剂且剂量合适。治疗抵抗的最新定义包括所有使用≥4种不同类型抗高血压药物的患者,无论其治疗期间的血压如何。对于使用≥5种抗高血压药物(包括噻嗪类利尿剂氯噻酮和盐皮质激素受体拮抗剂螺内酯)但血压仍未得到控制的患者,有人提出了“顽固性”高血压这一术语。必须排除尤其是由白大衣高血压和不依从规定药物治疗导致的“假性抵抗”,以便能够识别出具有“真正”治疗抵抗的患者。因此,在区分真性抵抗和假性抵抗之前,应使用“表观”抵抗这一术语。虽然表观抵抗在接受治疗的患者中患病率可能在10% - 15%之间,但由于缺乏适当研究,真正抵抗的确切患病率仍然未知,但可能相当低,其中包括相当比例的继发性高血压患者。一旦确定,大多数具有真正治疗抵抗的患者应主要通过增加利尿剂的使用来接受强化药物治疗。因此,顽固性高血压主要是一个诊断挑战:识别出具有真正抵抗的患者和继发性高血压患者。